Ensuring Optimal Integration of the GLP-1 Receptor Agonists: Review of the Latest Advances and Current Gaps in Care

Released On
January 30, 2020

Expires On
January 30, 2021

Media Type

Completion Time
60 minutes

Primary Care Providers: Physicians, Physician Assistants and Nurse Practitioners


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Boston University School of Medicine, Postgraduate Institute for Medicine, and Rockpointe.


Supported by an educational grant from Novo Nordisk Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Physicians — maximum of 1.0 ABIM MOC points
  • Physicians — maximum of 1.0 MIPS credits
  • Physicians — maximum of 1.0 AAFP Prescribed Credis
  • Nurses — 1.0 contact hour; 0.6 pharmacotherapy credit for APRNs.
  • Physicians Assistants — 1.0 AAPA Category CME credit

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for primary care providers (PCPs) involved in the education and management of adults eligible for treatment with GLP-1 RAs.

Program Overview

This program has been endorsed by the International Diabetes Center at Park Nicollet.

Click here for IDC T2D Educational Resources.

Almost 10% of the US population has diabetes, and half are not achieving glycemic goals. GLP-1 receptor agonists (GLP-1 RAs) work by decreasing glucagon secretion in a glucose-dependent manner and by activating the GLP-1 receptor, increasing insulin release in the presence of elevated glucose concentrations. There are common misperceptions about injectable GLP-1 RAs, including an overestimation of patient fears of injection pain, that cause these agents to be under-prescribed.

Based on recent clinical-trial data, one GLP-1 RA is approved not only as an adjunct to diet and exercise to improve glycemic control in adults with T2DM, but also to reduce the risk of major cardiovascular events in adults with T2DM and established cardiovascular disease. GLP-1 RAs represent a unique approach to T2DM treatment, with potential benefits extending beyond glucose control and including positive effects on body weight, blood pressure, and beta-cell function. This activity, “Ensuring Optimal Integration of the GLP-1 Receptor Agonists,” will update primary care clinicians on the safety and efficacy data for approved GLP-RAs, review the most recent guideline and expert recommendations for their use, and suggest strategies to overcome barriers to their use in appropriate patients.

Learning Objectives

This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

Upon completion of this activity, participants should be able to:

  • Evaluate the latest safety and efficacy data for each approved GLP-1 RA
  • Incorporate GLP-1 RAs into effective T2DM treatment plans based on the latest expert and guideline recommendations
  • Develop strategies to overcome misconceptions and barriers with the use of GLP-1 RAs in patients with T2DM


Richard Rosenthal, MD

Professor of Medicine
Division of Endocrinology, Diabetes, and Metabolism
Associate Chief Medical Quality Officer, Ambulatory Services
UAB Medicine
Birmingham, AL

Steering Committee

Sara M. Alexanian, MD

Director, Inpatient Diabetes Program
Clinical Associate Professor
Boston University School of Medicine
Section of Endocrinology, Diabetes, Nutrition, and Weight Management
Boston Medical Center
Boston, MA

M. Susan Burke, MD, FACP

Clinical Associate Professor of Medicine
Sidney Kimmel Medical College at Thomas Jefferson University
Senior Advisor
Lankenau Medical Associates
Lankenau Medical Center
Wynnewood, PA

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: cme@bu.edu.

ABIM MOC Designation Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through BUSM’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

MIPS Credit Designation

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

American Academy of Family Physicians (AAFP) Credit

This Enduring Material activity, Ensuring Optimal Integration of the GLP-1 Receptor Agonists Review of the Latest Advances and Current Gaps in Care , has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 1/30/2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Provider Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Rockpointe Corporation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.6 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Physician Assistant Credit Designation

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 1/30/2021. PAs should only claim credit commensurate with the extent of their participation.

Disclosures of Conflicts of Interest

This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty and Steering Committee Disclosures

The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Sara Alexanian, MD: Nothing to disclose

M. Susan Burke, MD, FACP: Speaker: Merck & Co, Inc.

Richard S. Rosenthal, MD: Nothing to disclose

Elliot Sternthal, MD (BUSM Course Director): Nothing to disclose

Non-faculty Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Terry Ann Glauser, MD, MPH; Blair St. Amand; Elizabeth Drury; Natalie Sanfratello, MPH; Brian Jack, MD; PIM Planners and Managers: Nothing to disclose

Disclosure of Unlabeled Use

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.



The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.